Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6- 18F-fluoro-L- phenylalanin PET

Journal of Nuclear Medicine

Volumn 53, Issue 9, 2012, Pages 1352-1358

  Rischke, H Christian ^a   Benz, Matthias R ^a,b   Wild, Damian ^a   Mix, Michael ^a   Dumont, Rebecca A ^a   Campbell, Dean ^b   Seufert, Jochen ^a   Wiech, Thorsten ^a   Rössler, Jochen ^a   Weber, Wolfgang A ^a,b   Neumann, Hartmut P H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F DOPA PET; Paraganglioma; Pheochromocytoma; SDHx; VHL

Indexed keywords

3,4 DIHYDROXY 6 FLUORO PHENYLALANIN F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PARAGANGLIOMA; PHENOTYPE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SDHB GENE; SDHD GENE; SENSITIVITY AND SPECIFICITY; VHL GENE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CHILD; DIHYDROXYPHENYLALANINE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARAGANGLIOMA; PHENOTYPE; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TUMOR BURDEN; YOUNG ADULT;

EID: 84866179443     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.101303     Document Type: Article

References (25)

1. DeLellis R, Lloyd R, Heitz P. Pathology and Genetics: Tumours of Endocrine Organs (IARC WHO Classification of Tumours). Lyon, France: IARC Press; 2004.
2. Reisch N, Peczkowska M, Januszewicz A, Neumann HP. Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens. 2006;24:2331-2339.
3. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812-8818.
4. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459-1466.
5. Calne DB, Langston JW, Martin WR, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature. 1985;317:246-248.
6. 18F DOPA whole body PET-initial results. Radiology. 2002;222:507-512.
7. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64-71.
8. 18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007;92:1237-1244.
9. 18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573-586.
10. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513-519.
11. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262-2269.
12. 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757-4767.
13. Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA. 2005;294:2057-2063.
14. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689-694.
15. 18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum [A]. 1990;41:275-281.
16. Grufferman S, Gillman MW, Pasternak LR, Peterson CL, Young WG Jr. Familial carotid body tumors: case report and epidemiologic review. Cancer. 1980;46: 2116-2122.
17. Tischler AS, Dichter MA, Biales B, Greene LA. Neuroendocrine neoplasms and their cells of origin. N Engl J Med. 1977;296:919-925.
18. Verrey F. System L: heteromeric exchangers of large, neutral amino acids involved in directional transport. Pflugers Arch. 2003;445:529-533.
19. Gazdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988;48:4078-4082.
20. Lee WY, Chang JW, Nemeth NL, Kang UJ. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats. J Neurosci. 1999; 19:3266-3274.
21. 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95:2800-2810.
22. 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922-3930.
23. 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779-2785.
24. 18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48:1599-1606.
25. 18F] fluoride. Appl Radiat Isot. 2009;67:1650-1653.